Johnson & Johnson (NYSE:JNJ) has a price target of $262 set by Morgan Stanley, indicating a potential upside of 16.73$100 billion and $101 billion for 2026, surpassing the Zacks Consensus Estimate.Despite challenges, the Innovative Medicine and MedTech segments are expected to drive growth, with adjusted earnings per share projected to be between$11.43 and $11.63.Johnson & Johnson (NYSE:JNJ), a well-known healthcare company with a diverse range of products in pharmaceut ...